Blackrock Neurotech

Phase A — Understand the business

Company Overview

Blackrock Neurotech is the incumbent of invasive brain-computer interfaces (BCI) — the company whose electrode has been inside more human brains, for more cumulative days, than any rival's. It was founded in 2008 by Marcus Gerhardt (co-founder, CEO/CFO) and Florian Solzbacher (co-founder, chairman & president), who met as schoolboys. HQ is Salt Lake City, Utah; reported headcount runs ~127–166 depending on source/date.

What it actually sells. Two distinct revenue logics sit inside one company:

1. The research razor — the NeuroPort / Utah Array. A silicon microelectrode array (the "Utah Array," invented by Univ. of Utah professor Richard Normann, commercialized by Blackrock) that records from hundreds of cortical neurons. It received the FDA's first-ever clearance for an implanted electrode panel that sends brain signals to a computer, and has been implanted in humans since 2004. This is a picks-and-shovels business: Blackrock has been the de-facto standard supplier of implantable electrodes, acquisition hardware (NeuroPort), and software to the academic/clinical BCI research community for ~20 years. "Nearly all BCIs implanted in humans have used Blackrock's technology" is the company's central marketing claim and is broadly corroborated by third-party coverage.

2. The product the razor is meant to become — MoveAgain. A full BCI system (array + decoder + software) that reads movement intent from a paralyzed patient's motor cortex to drive a cursor, keyboard, phone, wheelchair, or prosthetic. MoveAgain received FDA Breakthrough Device Designation in November 2021. It was originally slated for commercial release in early 2023 — a date that has slipped with no confirmed De Novo/PMA submission or clearance disclosed as of mid-2026.

A third layer is the next-gen pipeline: Neuralace, a sub-eyelash-thickness, >10,000-channel surface array unveiled at SfN 2022, positioned first as a research tool and later for visual-prosthesis applications (first-in-human Neuralace visual prosthesis targeted ~2028). Blackrock also acquired MindX (spatial-computing software) to build a "full-stack" BCI product, and in May 2025 partnered with Cognixion to distribute Axon-R, a non-invasive, AR-enabled BCI research headset — broadening reach beyond surgical implants.

Customers / suppliers / competitors. Customers historically = academic and clinical research institutions (BrainGate consortium members, university neuro labs) buying arrays and acquisition systems; the future customer is the paralyzed patient / their payer once MoveAgain clears. Suppliers = specialty microfabrication / semiconductor and biocompatible-materials vendors (Utah Array is a MEMS-style silicon part); not publicly itemized. Competitors: Neuralink, Synchron, Precision Neuroscience, Paradromics (detailed in Lens 3 & 7). our figures is empty — no concentration data is sourceable.

Contract structure. No recurring/take-or-pay structure is disclosed. The legacy business is transactional hardware sales to researchers (low volume, high-trust, sticky by reputation). The future business is a regulated medical-device model (per-implant + service/software), not yet live. n/a — revenue model not disclosed in dollars.

The one fact that reframes the whole company: since April 29, 2024, Blackrock Neurotech has been majority-owned by Tether (the stablecoin issuer), which invested $200M via its venture arm Tether Evo at a ~$350M valuation — making Tether the largest shareholder. (Note: the assignment brief framed this as a "December 2024" event; the sourced announcement date is 29 April 2024 — I am going with the documented date and flagging the discrepancy.) This is no longer a founder-controlled medtech startup; it is a strategic subsidiary of a crypto balance sheet with an explicit "human enhancement / brain-AI bridge" thesis (see Lens 9).

Supply Chain

Map: silicon + biocompatible materials → Utah Array microfabrication → NeuroPort system (array + percutaneous connector + acquisition hardware + decode software) → implanting neurosurgeon / research institution → end patient.

Named, sourceable stakeholders along the chain:

• Upstream IP origin: University of Utah (Richard Normann invented the array; Solzbacher chairs Utah's ECE department — a deep, named university umbilical that is both a moat and a related-party question, see Lens 9).
• Manufacturing: in-house microfabrication of the silicon array; specific foundry/MEMS subcontractors not publicly named n/a. This is a single-source, artisanal manufacturing process (the Utah Array is not a high-volume commodity part) — a scale chokepoint flagged in Lens 3.
• Software stack: bolstered by the MindX acquisition (spatial computing) and the Cognixion partnership (Axon-R non-invasive headset, May 2025).
• Clinical channel: the BrainGate academic consortium and individual neuro labs (Pitt/UPMC — Nathan Copeland; UC Davis / Stanford — Casey Harrell speech work) are the historical "distribution" of the research razor.
• Capital supplier (now controlling): Tether / Tether Evo.

Chokepoints: (1) Manufacturing does not obviously scale — hand-built silicon arrays are fine for ~30 research patients, unproven at commercial volume. (2) The percutaneous (skull-penetrating, wired) connector is the legacy architecture — a clinical and infection-risk chokepoint that fully-implanted/wireless rivals (Neuralink, Synchron) are explicitly engineered around. (3) Reimbursement path is undefined; no payer is in the chain yet.

Competitive Advantages (moats)

The moat is real but narrow, and it is made of one thing: time-in-human.

• Data & clinical-history moat (durable, hard to replicate): Blackrock arrays have been in ~30+ humans across research studies — the company claims 31 patients, "more than any company in the world," and a >30,000 cumulative patient-days record. (Tether's materials say "40+ individuals" — I treat 31 as the better-sourced clinical figure and flag the 40+ as a looser company/PR count; conflict surfaced, not silently resolved.) Twenty years of chronic-implant safety and performance data is a genuine regulatory and credibility asset a new entrant cannot buy.
• Regulatory-precedent moat: first FDA clearance for an implanted recording electrode + MoveAgain Breakthrough status (2021) = a head start in FDA familiarity.
• IP estate: ~65 patent documents across 27 families in 4 jurisdictions — meaningful but not dominant versus the better-capitalized field; PatentVest's own framing is that IP "will decide the future" and Blackrock is one of several serious holders, not the clear leader.
• Founder/academic embedding: Solzbacher's Utah chair = privileged access to talent and the foundational array science.

Where the moat is weak (this is the crux of the bear case):

• The core electrode is 2004-era technology, and its central failure mode is physical: Utah Arrays "often lose signal from over 60% of their electrodes within one year" as glial scar tissue encapsulates the penetrating silicon. This is a sourced, peer-reviewed limitation, not a competitor's talking point. The whole next-gen field (surface arrays, flexible films, endovascular) exists because penetrating silicon scars.
• Bargaining power is low and getting lower. Against suppliers: a small specialty buyer. Against the future customer (payers/hospitals): no leverage yet. Against capital: it sold control for $200M — the clearest possible revealed-preference signal that its standalone bargaining power was weak.

Verdict on the moat: Blackrock owns the past and present of implant BCI (most data, longest safety record, standard-issue research hardware) but does not clearly own the future architecture. The moat is a depreciating asset unless Neuralace (surface array) lands.

Segments

our figures is empty — no revenue/EBITDA split is sourceable. Constructing the segment logic from web sources, unquantified:

Geography: US-centric (Utah HQ, US research base) with the BrainGate consortium and international research collaborations; no geographic revenue split disclosed n/a. The honest read: this is effectively a pre-revenue-at-scale company with a small legacy hardware tail — the "segments" are really a pipeline. That is exactly why the +private and (arguably) +clinical framing applies.

Phase B — Measure performance (+private overlay: funding/valuation in place of earnings)

Funding & Valuation Trajectory (overlay-swapped from "Earnings Result")

No P&L exists. The scoreboard is the cap-table history — and the sources conflict sharply on the total, which is itself the finding:

• First funding round: September 15, 2009.
• Tracxn's tally: total ~$22.4M over 16 rounds from 13 investors; it labels a "Series B" on 2024-04-29 for $12.4M. (The date collision with the Tether deal suggests Tracxn is mis-bucketing part of the Tether investment.)
• PitchBook's tally: ~$250M raised.
• The reconciling fact: Tether Evo's $200M (April 29, 2024) at a ~$350M post/strategic valuation for a majority stake.

Reconciliation: pre-Tether the company had raised only on the order of ~$20–50M across 15 years (a strikingly thin raise for the category — consistent with a capital-starved, founder-run medtech that under-invested relative to the moment). The $200M Tether check roughly 4–10×'d total capital in one stroke and explains PitchBook's ~$250M. The April-2024 "$12.4M Series B" in Tracxn is most plausibly a fragment/mislabel of the Tether round, not a separate raise. Conflict surfaced, not resolved into a single false number.

• Notable historical backers (pre-Tether): Peter Thiel (angel), re.Mind Capital, plus grant capital from NIH/HHS and the EU. The reliance on non-dilutive grant money is a tell: the science was fundable by government, the commercialization was not, until Tether.
• Burn signal: the Tether money is explicitly earmarked "primarily to fund commercialization and roll-out" plus R&D — i.e. it is runway to cross the FDA/commercial chasm, not growth capital on top of a working business.

Read: the funding history is the story of a scientifically dominant, commercially under-capitalized company that was effectively rescued/acquired by a crypto balance sheet. The valuation step-up to $350M is real but modest next to peers (Lens 7).

Founder / Strategy Sentiment Trend (overlay: founder interviews & comms, not earnings calls)

No transcripts (transcripts/ empty). Tracking tone via interviews/press:

• Pre-Tether (Gerhardt, Medsider): classic mission-driven medtech-founder framing — "build a community," restore function to the paralyzed, patient-pioneer stories (Nathan Copeland fist-bumping Obama, 2016). Tone = patient-first, clinical, incrementalist.
• Post-Tether (Ardoino voice now dominant): the narrative shifts hard toward transhumanism — "human evolution," "enhancement of our species' potential," a "safe bridge between the human brain and AI computing," low-latency brain access to compute. Ardoino explicitly muses about consumer products beyond medical.
• 2025 cadence: real, shipped milestones — ALS patient speech restoration (Casey Harrell, 62 words/min, 125k-word vocab, voice cloned to sound like him — UC Davis/BrainGate work using Blackrock arrays); Axon-R non-invasive headset launch with Cognixion (May 2025).

Sentiment shift (the thing they started saying / stopped saying): the company stopped sounding like a careful clinical-device maker and started sounding like the medical front-end of a crypto founder's species-uplift thesis. That is simultaneously a capital unlock and a brand/regulatory risk — FDA reviewers and disability advocates respond very differently to "restore speech to ALS patients" than to "merge humans with AI."

Cap Table, Secondary Marks & Mechanism Comps (overlay-swapped from "Comps")

Cap table quality. The defining feature is single-strategic control: Tether/Tether Evo holds the majority. This is the opposite of the IPO-proximity tell you want — there is no crossover fund (Fidelity/T. Rowe/Coatue) on the cap table signaling an S-1 runway; instead there is a controlling crypto parent whose own regulatory status (Lens 10) is unresolved. Earlier syndicate: Thiel + re.Mind + government grants — credible but small.

Secondary marks — the genuinely useful +private datapoint: Blackrock Neurotech shares trade on private secondary markets. Hiive lists a price of ~$0.83/share; the name is also offered on NasdaqPrivateMarket and EquityZen. A live secondary venue is a partial path-to-liquidity and a reality-check on the $350M mark — but a per-share number without a sourced share count can't be turned into a clean implied valuation here n/a — share count not sourced. Flag for refresh: track whether the secondary mark drifts above/below the April-2024 $350M strike.

Peer set — valuation comps (private BCI, USD):

The comp that matters: Blackrock has the most human data and by far the lowest valuation — ~$350M vs Neuralink's ~$9.6B, a ~27× gap. The market is not paying for time-in-human; it is paying for next-gen architecture, bandwidth, and capital firepower — exactly where Blackrock is weakest. Mechanism comps (the +clinical flavor): on the speech-BCI axis Blackrock-array work is at the frontier (62 WPM); on the electrode-architecture axis it is the legacy incumbent being routed around.

Market size context: implantable-BCI TAM ~$1.51B (2025) → ~$7.46B (2035), ~17.5% CAGR — a real but still-emerging market, i.e. years of cash-burn before category revenue is large.

Catalysts & Value-Inflection Events (overlay: funding/product/clinical events)

The events that have moved (or would move) this private name's perceived value:

• Apr 29, 2024 — Tether $200M majority investment at ~$350M. The single biggest re-rating; converted a capital-starved founder shop into a funded subsidiary.
• 2023–24 — ALS speech restoration (Casey Harrell, 62 WPM) — the strongest clinical-credibility catalyst; demonstrated frontier capability on Blackrock arrays.
• Nov 2021 — MoveAgain FDA Breakthrough Designation — the regulatory on-ramp.
• May 2025 — Axon-R / Cognixion non-invasive headset — TAM-broadening optionality beyond surgery.
• 2016 — Nathan Copeland fist-bumps Obama via Blackrock BCI — the enduring PR/credibility anchor.

Forward catalysts (what would actually re-rate it): (1) a De Novo / PMA submission or clearance for MoveAgain — the slipped 2023 launch is the overhang; (2) a new priced round or a secondary mark materially above $350M (or below — a down mark would be a red flag); (3) Neuralace first-in-human; (4) any Tether regulatory event (positive: GENIUS-Act-compliant US entity stabilizes the parent; negative: a DOJ action — see Lens 10).

Pattern read: value here reacts to clinical milestones and the Tether relationship, far more than to the legacy hardware business. It is a catalyst-driven, binary-ish profile typical of pre-commercial implant medtech.

Phase C — Judge people & books

Management

• Marcus Gerhardt — Co-founder, CEO & CFO. Built Blackrock from a 2008 academic-adjacent startup into the most-implanted BCI maker. Track record: durable scientific/clinical credibility and category leadership on time-in-human; but under his tenure the company under-raised for 15 years and ultimately ceded majority control for $200M — a mixed capital-allocation verdict (he kept the science alive on grants but couldn't independently fund commercialization). CEO and CFO in one person is a governance thinness flag.
• Florian Solzbacher — Co-founder, Chairman & President; Chair of ECE at the University of Utah. Deep technologist (NAE-affiliated; founder of multiple "Blackrock Microsystems"/Sentiomed/First Sensor entities). The Utah chair + company chairman dual role is a genuine related-party surface (university IP, talent, facilities flowing to a company he chairs) — common in deep-tech spinouts, but to be probed.
• Tether / Paolo Ardoino — controlling shareholder (since Apr-2024). Now the decisive voice. Brings (a) a very large balance sheet (Tether reported reserves backing ~$186.5B USDT at end-2025, with sizable reported profits) and (b) a transhumanist strategic agenda that re-frames the company. This is the central management fact: the founders still run the lab, but strategy, capital allocation, and risk appetite now sit with a crypto issuer whose own regulatory standing is unsettled.
• EY Entrepreneur of the Year 2023 (Mountain West) finalists — Gerhardt & Solzbacher — a minor external validation.

Founder vs professional manager: founder-led on the science, strategic-acquirer-controlled on the money. For this stage, that means deep cash but mission drift risk — the gravitational pull from "FDA-cleared medical device for paralysis" toward "consumer brain-AI interface" could misallocate the runway and complicate the regulatory story.

Forensic Red Flags

No audited financials exist — so classic statement forensics (revenue recognition, receivables vs revenue, SBC flattering non-GAAP) are n/a — private, unaudited. The forensic work re-points to governance, structure, and the parent:

1. Controlling-shareholder / parent risk (the dominant flag). Tether is the majority owner, and Tether itself carries active regulatory overhang: reporting (denied by Tether) of a DOJ / Manhattan federal investigation into money-laundering and sanctions exposure, and a GENIUS Act foreign-issuer compliance regime (18–36 month window; Tether responded with a US-specific stablecoin USAT and an El Salvador HQ move). A material adverse event at the parent could starve or destabilize the subsidiary — this is the single most important non-obvious risk in the whole dossier, and it is structural, not operational.
2. Reserve/transparency questions at the parent flow downhill to funding-durability risk for Blackrock: if Tether's reserves or legal status were impaired, the "commercialization runway" thesis weakens.
3. Related-party academic structure — Solzbacher's Utah chair ↔ company chairmanship ↔ foundational IP (Normann/Utah). To be examined for IP-license and conflict terms n/a — terms not disclosed.
4. Single-person CEO/CFO = weak financial-controls separation.
5. Valuation/clinical-claim consistency — the "40+ individuals" (Tether PR) vs "31 patients" (clinical sources) discrepancy is minor but is exactly the kind of soft inflation to watch in promotional comms now that a crypto marketer controls the narrative.

Regulatory findings (required sub-section). Per the pre-fetched regulatory/regulatory-findings.md (generated 2026-06-17, sources SEC EDGAR EFTS LR + AAER): total_sec_findings: 0 — Blackrock Neurotech has no CIK, is private, and cannot be the subject of an EDGAR enforcement search. Non-SEC web search ("Blackrock Neurotech" (FTC OR DOJ OR FDA OR consent decree OR settlement OR penalty) enforcement) returned no material enforcement action, FDA warning letter, lawsuit, or patent-dispute hit against Blackrock Neurotech itself — the legal/enforcement headlines in the search space attach to Tether (the parent), not to the operating company, and to BlackRock Inc. (the unrelated asset manager). Conclusion: No material regulatory or legal findings against Blackrock Neurotech directly — verified via SEC EDGAR EFTS (LR, AAER, total 0), web enforcement search, and the absence of any 10-K (private, no filer) as of 2026-06-17. The material regulatory risk is inherited from the controlling parent, Tether, not generated by the company. (Unaudited per public sources.)

Phase D — Project & stress-test (+private overlay: IPO-readiness in place of EPS)

IPO-Readiness & Path-to-Tradeable (overlay-swapped from "Forward Projection"; no rNPV/EPS model — no P&L)

There is no research/private-watch.json to ground a stage/readiness/catalyst field, so this is reconstructed / and should be written into a private-watch entry on the next pass.

Path-to-tradeable, today: low IPO-readiness on a 12–24 month horizon. Reasoning:

• No crossover-fund cap-table signal; instead a controlling strategic (Tether) — strategics typically hold, and an IPO would dilute/complicate Tether's control and its "human-enhancement" agenda. An IPO is not the obvious exit; a continued strategic hold (or eventual roll-up) is more likely.
• No disclosed S-1-grade financials, no confirmed commercial product (MoveAgain unclear post-slip), no audited revenue at scale.
• Liquidity reality: the realistic near-term liquidity is the secondary market (Hiive ~$0.83/sh; NasdaqPrivateMarket; EquityZen), not a public listing.

Milestones that would unlock an S-1 / public path (the watch-list):

1. MoveAgain De Novo/PMA submission → clearance (the gating commercial event).
2. First commercial revenue from cleared implants + a reimbursement pathway.
3. A priced primary round with a crossover investor, or a secondary mark sustainably > the $350M strike.
4. Clarity on Tether's own regulatory status (GENIUS-Act-compliant US structure resolved cleanly) so a subsidiary IPO is even feasible.
5. Neuralace first-in-human (de-risks the architecture-obsolescence bear case).

Estimated window: no credible IPO inside ~24 months; this is a 2027+ at the earliest story, and possibly never public (strategic hold). Brier-style binary forecast to log (NOT logged here — --watchlist/breadth mode skips our model create): "Blackrock Neurotech files an S-1 / goes public before 2028-06-30" — subjective p ≈ 0.10. "MoveAgain receives FDA marketing authorization (De Novo or PMA) before 2027-06-30" — p ≈ 0.30. (Logged in the dossier as the scoreable claims; not written to the forecast tracker per breadth-loop rules.)

Bull vs Bear

Bull case. Blackrock owns the one asset a competitor cannot buy with money: two decades and ~31 humans of chronic-implant clinical data, the first-ever FDA-cleared recording electrode, MoveAgain Breakthrough status, and frontier results (62-WPM ALS speech). It is radically cheaper than Neuralink (~$350M vs ~$9.6B, ~27×) while leading on the metric — patient-data depth — that FDA and clinicians arguably weight most. With Tether's balance sheet now behind it, the historic constraint (capital starvation) is removed; if MoveAgain clears and Neuralace lands, a name carrying the deepest safety dossier in BCI is dramatically under-marked. Secular tailwind: a $1.5B→$7.5B implant-BCI TAM. Capital allocation upside: a controlling parent with deep pockets and a long horizon can fund the FDA chasm that kills most medtech.

Bear case (the 2–3 things that permanently impair it).

1. The electrode is the wrong horse. Penetrating silicon scars — peer-reviewed evidence shows >60% electrode signal loss within a year. If chronic reliability is the game, the surface/flexible/endovascular architectures (Precision, Synchron) and high-density next-gen (Neuralink, Paradromics) may render the Utah Array a legacy part. Blackrock's answer (Neuralace) is early and unproven in humans.
2. Controlling-shareholder contagion. A DOJ/sanctions action or GENIUS-Act failure at Tether could cut the funding lifeline or saddle the company with a toxic parent — a risk entirely outside the operating team's control.
3. Commercialization keeps slipping. The 2023 MoveAgain launch did not visibly happen; no confirmed De Novo/PMA as of mid-2026. A company that has been "about to commercialize" for years, now run by crypto marketers drifting toward "consumer brain-AI," may never cross the regulatory chasm as a focused medical device.

Pre-mortem (18 months out, thesis broke — what happened?): Tether took a regulatory hit and pulled back / got distracted; MoveAgain's De Novo stalled on chronic-reliability data (the scarring problem in front of FDA); a better-capitalized rival (Neuralink/Precision) shipped a cleared, more durable system first; the secondary mark drifted below $350M and the "deepest data set" turned out to be the wrong, depreciating moat.

Is the ~$350M mark too high or too low? Genuinely ambiguous. Cheap vs peers on data depth; expensive if the electrode architecture is obsolescing and commercialization never lands. The honest answer is the mark is a bet on whether time-in-human or next-gen-architecture wins — and that is unresolved.

Contrarian view (what the market refuses to see): consensus treats Blackrock as the also-ran of BCI because it's cheap and old-tech. The contrarian read: FDA approves safety dossiers, not bandwidth specs — and in a regulated medical-device race, the company with 20 years of human chronic-implant data may have a regulatory moat the market is mispricing to ~1/27th of Neuralink. The catch: that thesis dies the day a flexible/surface array proves equal-or-better chronic reliability with a cleaner safety profile — which is precisely what the entire next-gen field is built to do.

Devil's Advocate (short-seller)

As a skeptical short-seller (acknowledging you can't short a private):

• Structural break in how it makes money: the legacy razor (research-lab hardware sales) is a small, flat, non-scalable business; the future razor (MoveAgain implants) is not cleared and keeps slipping. There may be no large, durable revenue engine here at all — just grant-funded science plus a strategic parent's subsidy.
• Revenue concentration: what little revenue exists is concentrated in a niche academic buyer base that is itself migrating to rival architectures for new programs. Concentration shifts against Blackrock as labs adopt surface/high-density arrays.
• Why the moat is weaker than bulls think: the moat is historical data on a depreciating electrode. Data depth doesn't help if the device itself is being designed out of the field for chronic-reliability reasons.
• Most dangerous underestimated competitor: Precision Neuroscience — founded by a Neuralink co-founder (Benjamin Rapoport), a non-penetrating surface film (Layer 7) that sidesteps the scarring problem, already with an approved implant in 2025 and "more than a dozen" subjects, raising $100M+. It attacks Blackrock's exact weakness (penetration/scarring) with a credible founder and fresh capital.
• Worst capital-allocation / governance moves: 15 years of under-raising culminating in selling majority control to a crypto issuer under DOJ scrutiny; CEO=CFO; chairman is the university chair that supplies the foundational IP (related-party surface).
• Assumptions that must hold for today's $350M: (a) MoveAgain clears FDA in a reasonable window; (b) the Utah Array's chronic-reliability problem is survivable in front of regulators; (c) Tether stays solvent, legal, and committed; (d) "deepest human data" remains a valued moat rather than a stranded one. Several of these are coin-flips.
• If growth/commercialization disappoints by 20–30%: for a pre-commercial name the asymmetry is brutal — a stalled De Novo or a Tether shock could mark it down well below $350M; there is no earnings floor.
• Single scenario that permanently impairs it: a competitor's surface/flexible array wins FDA clearance with superior chronic reliability before Blackrock commercializes — at which point Blackrock's entire moat (data on a penetrating electrode) becomes a museum piece, and a distracted, crypto-controlled balance sheet has little incentive to keep funding a losing architecture. Plausibility: moderate and rising.

Management Questions (ordered by information value)

1. Where exactly is MoveAgain in the FDA process today — has a De Novo or PMA been submitted, and what is the realistic clearance timeline? (The whole commercial thesis hinges here.)
2. How are you solving the glial-scarring / electrode-signal-loss problem that costs penetrating arrays >60% of channels within a year — is Neuralace (surface) the answer, and what's its human timeline?
3. What is Tether's commitment structure — is the $200M fully funded/drawn, are there milestones or claw-backs, and what happens to Blackrock if Tether faces a material regulatory action?
4. Is the strategic priority the FDA medical-device path, or the Ardoino "consumer brain-AI" vision — and how do you keep the former from being starved by the latter?
5. What is the actual annual revenue and burn, and how many months of runway does the Tether capital provide at the current spend?
6. What is the reimbursement strategy for MoveAgain — CMS/payer pathway, coding, expected per-patient economics?
7. How does the Utah Array scale to commercial manufacturing volumes from artisanal research-lab production, and at what unit cost/yield?
8. Reconcile "40+ individuals" vs "31 patients" — what is the precise current implant count and how many remain actively functioning?
9. What are the IP-license terms with the University of Utah, and how do you manage the conflict of the chairman also chairing the university department that owns the foundational science?
10. Why should the deepest human-data set win when the entire field is moving to architectures designed to avoid your electrode's failure mode?
11. What is your answer to Precision Neuroscience's non-penetrating Layer 7 and its 2025 approval — where are you faster or safer?
12. Is an IPO a realistic exit, or is the plan a permanent strategic hold / eventual roll-up under Tether?
13. How do you separate financial controls with a single CEO/CFO, and is a dedicated CFO planned now that you're a funded subsidiary?
14. What did the $200M change operationally — headcount, manufacturing capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs., clinical-trial scope — in concrete numbers since April 2024?
15. What is the single technical or regulatory failure that would most likely break the company, and what are you doing to de-risk it?